TOP

橫幅

Corporate Executives

Howard Lee,Chairman
Howard LeePh.D.Chairman
Howard Lee, Ph.D. is the Chairman of EASYWELL BIOMEDICALS. He is currently a partner of the CID Group which is an international fund of over $1.3B with headquarters in Taipei,Taiwan and Shanghai,China. He is also the Chairman of TAHO Pharmaceuticals, Inc. as well as Transwell Biotech Co., Ltd. Dr. Lee has over twenty years of experience in investment banking, global healthcare, venture capital and project management. He has initiated more than US$400M of global equity investments in the healthcare field. Previously he served for five years as the Managing Director of Silver Biotech Management Inc. (SBM). The eleven years prior to SBM, Dr. Lee was the President & CEO of CDIB Biotech USA Investment Co. Ltd. In Dr. Lee’s early career he accumulated vast industrial experience from managing environmental engineering projects in various diversified industries. He received his Ph.D. degree in Chemistry from University of Southern California, USA.
Robinson HsuPresident
Robinson HsuPresident
Mr. Robinson Hsu has developed an expertise in sales, marketing, strategic planning, and corporate management in IT through his vast experience in the medical device industry. He received his MBA degree from National Taiwan University and a Master’s degree in Industrial Management from Fudan University in Shanghai, China.
James Lee, Ph.D.Chief Operating Officer
James Lee, Ph.D.Chief Operating Officer
James Lee, Ph.D. has extensive experience in both medical device and pharmaceutical industries. As the founder of Magnifica, Inc. James Less had successfully obtained FDA approvals of APIs, optimized chemical synthesis for various pharmaceutical compounds, established API trading business, and developed Rx-to-OTC pharmaceutical products. He previously worked with Karl Storz Endoscopy, Inc. for a new product launch; and was able to obtain FDA clearance/approval for over 25 medical surgical device sets. He was previously employed by Baxter International and served as President of Pharmaports. He received his Ph.D. degree in Chemistry and Master’s in Biomedical Engineering from University of Southern California and earned his BA in Biochemistry from Columbia University, USA.
Yu-Hsing Tu, Ph.D.Chief Science Officer
Chairman, Tulex Pharmaceuticals, Inc.
Yu-Hsing Tu, Ph.D.Chief Science Officer
Chairman, Tulex Pharmaceuticals, Inc.
Yu-Hsing Tu, Ph.D. joined EASYWELL BIOMEDICALS, INC., in 2014 and is leading the build-up of pharmaceutical operations in product development under cGMP environments. He has 25+ years of pharmaceutical industry experience and is the inventor/co-inventor of many innovative technologies that received patents as well as multiple product approvals. Prior to joining Tulex Pharmaceuticals Inc., Yu-Hsing worked for Tris Pharma, Medeva (currently UCB) and Solvay. He is a pharmacist by training and holds a Ph.D. degree in pharmaceuticals from University of Iowa, USA.
Sean C.-H Chen, Ph.D.General Manager, Regenerative Medicine Division
Sean C.-H Chen, Ph.D.General Manager, Regenerative Medicine Division
Sean C.-H Chen, Ph.D. is the founder of Transwell Biotech and is responsible for business alliance and strategic planning for the company and its products. Dr. Chen was a full time faculty member for several years at the National Taiwan University, College of Medicine before joining the biopharmaceutical industry. His industrial experience includes clinical research operation as well as product development utilizing NCE, 505(b)(2) and ANDA strategies. After graduating from the National Taiwan University, Dr. Chen further received his doctoral degree in Neurophysiology at Ohio State University and worked as a Post-doc research fellow at MIT-Whitehead Institute.
Bin-Ru She, Ph.D.Chief Technical Officer, Regenerative Medicine Division
Bin-Ru She, Ph.D.Chief Technical Officer, Regenerative Medicine Division
Bin-Ru She, Ph.D. has 15 years of hands-on experience in Cell Therapy and Regeneration Medicine. She is one of the regional’s leading experts in the field of Cell Therapy and Regeneration Medicine in Asia. Before taking this industry position, Dr. She was the senior scientist at Industrial Technology Research Institute (ITRI) and helped to build and supervise the operation of ITRI’s high quality, well reputed Cell Manufacturing Facility. Dr. She graduated from the National Taiwan University, and received her Ph.D. in Molecular Biology from Indiana University-Bloomington. She did her post-doctorate training at the Salk Institute and the Academia Sinica in Taiwan.
Richard HsiehChief Quality Officer
Richard HsiehChief Quality Officer
Mr. Richard Hsieh has over 20 years of experience in QC/QA and GMP regulations. He has worked for companies in Taiwan, U.S.A, China and Europe. He received his MBA degree in International Business from the National Taiwan University and his Bachelor’s degree in Industrial Engineering from National Chiao Tung University, Taiwan.
Sue ChengChief Financial Officer
Sue ChengChief Financial Officer
Mrs. Sue-Chun Cheng has more than 20 years of experience in securities, auditing, finance, accounting, administration, and strategic planning. Prior to joining EASYWELL BIOMEDICALS, she worked with Deloitte & Touche, Coretronic Corporation and Capital Securities Corporation. She received her Bachelor Degree in Accounting from Feng Chia University, Taiwan. She is currently seeking a Master Degree in Economics at National Chiao Tung University.